24 01, 2018

Autism and automatic analysis of hand movements

2018-01-25T15:11:38+00:00January 24th, 2018|

Kinematics could provide earlier and more specific information than clinicians on developmental problems in general, and those specific to Autism Spectrum Disorder in particular, a published study by Ariana and Necker Children Hospital finds. […]

16 01, 2018

Ariana’s KEM® analysis shows positive impact on patient Quality of Life for ValiSeek VAL401 in Phase II trial for NSCLC patients

2018-01-17T12:28:23+00:00January 16th, 2018|

Further positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients. VAL401 treatment has a measureable improvement on patient Quality of Life, in addition to a significant impact on survival. London, Paris and Boston, 16 January 2018: Ariana Pharma and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, today provided an update on the clinical progress and results of VAL401, the anti-cancer compound developed by ValiSeek. Following on from the announcement on 12 December 2017 regarding the overall survival results from the completed Phase II Clinical Trial of VAL401 in Tbilisi, Georgia, in the treatment of late stage non-small [...]

12 12, 2017

Ariana®’s KEM® data analysis shows positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients

2018-01-16T10:09:25+00:00December 12th, 2017|

London, Paris and Boston, 12 December 2017: Ariana Pharma and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, today provided a positive update on the clinical progress of VAL401, the anti-cancer compound developed by ValiSeek. Using Ariana’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, the data analysis demonstrates that the VAL401 treatment has a statistically significant improvement in Overall Survival for patients with non-small cell lung cancer compared to those receiving no treatment. […]

4 11, 2017

CTAD 2017 (Boston, USA | 1-4 Nov)

2017-11-07T13:11:30+00:00November 4th, 2017|

Dr Mohammad Afshar (Ariana CEO) is presenting on the analysis of Phase 2a trial results using Ariana’s KEM® artificial intelligence platform at CTAD 2017 (10th Clinical Trials on Alzheimer’s Disease) in Boston, USA on 4 November. […]

12 10, 2017

Anavex incorporating Ariana’s KEM® AI platform in Alzheimer’s precision medicine approach

2017-10-18T11:38:59+00:00October 12th, 2017|

Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients ANAVEX2-73 demonstrates desirable PK/PD properties, describing the relationship between drug concentration and the effect observed. Anavex is incorporating advanced Artificial Intelligence platform for the analysis of Phase 2a results with the aim to increase the chances of success in forthcoming Phase 2/3 study. NEW YORK, October 12, 2017 – Anavex Life Sciences Corp. (Nasdaq: AVXL) today announced pharmacokinetic (PK) and pharmacodynamic (PD) data for ANAVEX2-73 from its positive Phase 2a study in mild-to-moderate Alzheimer’s disease patients. ANAVEX2-73 targets the sigma-1 receptor, which regulates neuroplasticity and cellular homeostasis. [...]

26 06, 2017

WIN 2017 (Paris | Jun 26-27)

2017-06-26T10:48:45+00:00June 26th, 2017|

Meet the Ariana team of Dr Mohammad Afshar (CEO) and Dr Mariana Kuras (CTO) at the WIN 2017 Symposium this week. […]

16 05, 2017

API 2017 (Panama | May 16-20)

2017-05-16T20:31:42+00:00May 16th, 2017|

Two posters highlighting the use of Ariana’s Real World Evidence (RWE) platform for large scale data mining of healthcare records are to be presented at API 2017 (Asociacion Panamericana de Infectologia) – XVIII Congresso Panamericano de Infectologia, Panama, 16-20 May 2017. […]

Load More Posts